View : 17 Download: 0

Successful rechallenge with gefitinib for an initial erlotinib-responder with advanced lung adenocarcinoma

Title
Successful rechallenge with gefitinib for an initial erlotinib-responder with advanced lung adenocarcinoma
Authors
Hong S.C.Sim Y.S.Lee J.H.Ryu Y.J.Chang J.H.
Ewha Authors
장중현이진화류연주
SCOPUS Author ID
장중현scopus; 이진화scopus; 류연주scopus
Issue Date
2011
Journal Title
Tuberculosis and Respiratory Diseases
ISSN
1738-3536JCR Link
Citation
vol. 71, no. 4, pp. 286 - 290
Indexed
SCOPUS; KCI scopus
Abstract
Although failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of administering erlotinib as a second EGFR TKI after resistance of gefitinib as the first TKI has been well known. However, good response to gefitinib after an initial response to erlotinib has been rare. We report that a 45-year-old woman (never smoked), with lung adenocarcinoma and EGFR mutation, showed an initial response to erlotinib, and then responded to gefitinib again. Copyright©2011. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.
DOI
10.4046/trd.2011.71.4.286
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE